De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Küemmel, Eva‐Maria Grischke, Michael Braun, Doris Augustin, Jochem Potenberg, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Christine zu Eulenburg, Ronald Kates, Rachel Wuerstlein, Hans Kreipe, Nadia Harbeck, Raquel von Schumann, Walther Kuhn, Silke Polata, Wojciech Bielecki, Ralf Meyer, Marianne Just, Susanne Kraudelt, Wulf Siggelkow, Heidi Wortelmann, Anke Kleine-Tebbe, Lena Leitzen, Heidrun Kirchhof, Petra Krabisch, John Hackmann, Reinhard Depenbusch, K. Gnauert, Peter Staib, Antje Lehnert, Oliver Hoffmann, Susanne Briest, Christoph Lindner, Volker Heyl, Leila Bauer, Christoph Uleer, Svjetlana Mohrmann, Nicole Viehstaedt, Wolfram Malter, Theresa Link, Nana Buendgen, Joke Tio